SPRY
ARS Pharmaceuticals, Inc
4.30$
+5.4%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Cash Flow
ARS Pharmaceuticals, Inc (SPRY) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -61 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 20 | Q2 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.6 | -5.4 | -12 | -14 | -19 | -21 | -6.9 | -7.0 | -5.7 | -20 | -12 | -17 | -13 | -17 | -6.7 | -7.3 | -14 | 42 | -41 | -40 | -47 | -43 | -45 | -61 | -196 | |
| 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.4 | 0.1 | 0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.5 | -1.7 | 0.3 | 2.4 | -1.5 | 0.4 | 0.4 | 1.6 | |
| – | – | 0.9 | 0.9 | 0.9 | 0.2 | 0.3 | 0.4 | 0.5 | 4.8 | 2.3 | 2.1 | 2.6 | 2.3 | 3.3 | 3.4 | 3.6 | 4.3 | 5.3 | 5.4 | 5.7 | 5.7 | 7.4 | 12 | 31 | |
| – | – | 0.9 | 0.9 | 0.6 | 0.6 | 0.4 | 0.4 | 6.1 | -9.2 | 2.3 | 2.1 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| -2.8 | 0.5 | 1.9 | 5.1 | -2.0 | -3.4 | 0.0 | -1.0 | -0.3 | -0.8 | 2.1 | 0.3 | 1.0 | -11 | 2.2 | 3.8 | -1.5 | -11 | -10 | -1.1 | -1.1 | -7.5 | 8.6 | -13 | -13 | |
| 0.0 | 0.0 | 0.0 | 0.7 | 0.1 | 0.6 | 0.0 | 0.0 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.1 | 0.1 | 0.0 | 0.1 | 0.3 | 0.1 | 0.1 | 0.2 | 0.0 | 0.0 | 0.0 | 0.2 | |
| 0.0 | 0.0 | 0.0 | -0.7 | -40 | -26 | 0.0 | 0.0 | 0.0 | -0.1 | -112 | 45 | -47 | 26 | -8.5 | -13 | 17 | -102 | 29 | 49 | -45 | 24 | 28 | 42 | 48 | |
| – | – | – | – | – | – | – | – | 1.2 | -0.8 | 1.3 | 2.9 | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | -0.9 | -0.9 | -0.9 | -0.9 | -0.9 | -0.9 | -0.9 | -8.7 | – | – | – | – | – | – | – | – | – | – | – | -0.7 | – | – | – | |
| 21 | 12 | -0.1 | 0.3 | 0.1 | 0.3 | -0.9 | -0.6 | -1.6 | 194 | 1.3 | 2.9 | 0.9 | 1.8 | 0.3 | 0.5 | 0.7 | 71 | 0.7 | 2.7 | 100 | 1.1 | 0.2 | 3.2 | 105 | |
| -10.0 | – | -12 | -15 | -59 | -47 | -7.9 | -15 | -7.3 | 173 | -123 | 31 | -58 | 10 | -15 | -19 | 3.0 | 11 | -11 | 12 | 8.0 | -18 | -17 | -16 | -43 | |
| -7.7 | -5.4 | -12 | -15 | -19 | -22 | -6.9 | -7.0 | -5.7 | -21 | -13 | -17 | -13 | -17 | -6.8 | -7.3 | -15 | 42 | -41 | -40 | -47 | -43 | -45 | -61 | -197 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.